All In Biotech

Drug Trial Radar · NCT07472647

SYS6090 Combination Therapy in Advanced Lung Cancer

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

596

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Feb 28, 2029

Study completion Feb 28, 2030

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.

Conditions

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

Interventions

  • SYS6090 + pemetrexed + platinum-based chemotherapyDrug

    In this group, participants will receive SYS6090 in combination with pemetrexed and platinum-based chemotherapy.

  • SYS6090 + paclitaxel + platinum-based chemotherapyDrug

    In this group, participants will receive SYS6090 in combination with paclitaxel and platinum-based chemotherapy.

  • SYS6090 + docetaxelDrug

    In this group, participants will receive SYS6090 in combination with docetaxel.

  • SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapyDrug

    In this group, participants will receive SYS6090 in combination with pemetrexed, bevacizumab, and platinum-based chemotherapy

  • SYS6090 + SYS6010Drug

    In this group, participants will receive SYS6090 and SYS6010.

  • SYS6090 + etoposide + platinum-based chemotherapyDrug

    In this group, participants will receive SYS6090 in combination with etoposide and platinum-based chemotherapy.

  • SYS6090 + chemotherapy or other anticancer therapyDrug

    In this group, participants will receive SYS6090 in combination with chemotherapy or other anticancer therapies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT) (Phase Ib)Time frame: Approximately 21 days.
  2. Adverse Events (AEs) (Phase Ib)Time frame: Up to 90 days after the last administration
  3. Objective response rate (ORR) (Phase II)Time frame: Through out the study (up to 2 years)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.